We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
T2 Biosystems Inc | NASDAQ:TTOO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.295 | -8.79% | 3.06 | 2.98 | 3.18 | 3.70 | 2.9616 | 3.29 | 507,256 | 23:36:23 |
The presentation, A Rapid, Direct-from-Blood Diagnostic to Address Infections from Multidrug Resistant Organisms (MDROs), will take place on Monday, June 17 at 12:00 pm and will feature Tom Lowery, PhD, chief scientific officer, T2 Biosystems. During the presentation, Dr. Lowery will highlight how rapid, direct-from-blood diagnostics – such as the T2Bacteria®, T2Candida® and T2Resistance™ Panels – can help slow the spread of MDROs and improve patient outcomes. Dr. Lowery will also highlight new data supporting potential future uses of the T2MR® technology for biodefense applications.
During the presentation, Dr. Lowery will share a number of updates on the clinical utility of T2 technology that further prove T2MR’s ability to enable high-sensitivity, blood culture-independent detection of pathogens at ultra-high sensitivity, including:
“Like so many of our peers at this year’s Biodefense World Summit, we are increasingly concerned by the serious public health threat posed by MDROs on a global scale,” said John McDonough, president and chief executive officer of T2 Biosystems. “Our unique technology is a proven weapon in the fight against the spread of these dangerous biological agents, providing earlier detection and reducing the unnecessary use of inappropriate antibiotic therapy, which is a driver of drug-resistance in these organisms. We also are excited with the potential to expand our technology for the detection of Candia auris, which is already available as a research-use-only product, and other pathogens that are relevant to the field of biodefense.”
T2 Biosystems is the company behind the T2Bacteria Panel, the first and only FDA-cleared test to identify sepsis-causing bacterial pathogens directly from whole-blood in 3 to 5 hours without the wait for blood culture, enabling patients to be placed on targeted therapy faster, improving those patients’ outcomes. The T2Bacteria Panel is one of several panels that are approved or in development that are run on the Company’s T2Dx® Instrument, which is powered by miniaturized magnetic resonance (T2MR) technology.
About T2 Biosystems T2 Biosystems, a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease.
Media Contact: Gina Kent, Vault Communications gkent@vaultcommunications.com 610-455-2763
Investor Contact: Zack Kubow, W2O Group zkubow@w2ogroup.com 415-658-6436
1 Year T2 Biosystems Chart |
1 Month T2 Biosystems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions